Inclacumab

Summary

Inclacumab (CHEMBL2109488) is a phase-3 clinical-stage antibody targeting SELP; indicated across 3 conditions including coronary artery disorder and myocardial infarction.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (SELP)
• Indications: 3 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109488
Name	Inclacumab
Type	Antibody
Max phase	3

Also known as: Inclacumab, RG1512, RO-4905417, RO4905417, INCLACUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SELP	selectin P (CD62)	Binding			P16109

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SELP.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	SELP
Platelet degranulation	1	SELP
Cell surface interactions at the vascular wall	1	SELP
Platelet activation, signaling and aggregation	1	SELP
Response to elevated platelet cytosolic Ca2+	1	SELP

Dominant GO biological processes

GO term	Targets
positive regulation of leukocyte migration	1
inflammatory response	1
cell adhesion	1
heterophilic cell-cell adhesion	1
leukocyte cell-cell adhesion	1
positive regulation of platelet activation	1
calcium-dependent cell-cell adhesion	1
response to lipopolysaccharide	1
regulation of integrin activation	1
response to cytokine	1
defense response to Gram-negative bacterium	1
leukocyte tethering or rolling	1
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
cell-cell adhesion	1
positive regulation of leukocyte tethering or rolling	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
coronary artery disorder	2	MONDO:0005010	EFO:0001645
myocardial infarction	2	MONDO:0005068	EFO:0000612
peripheral arterial disease	1	MONDO:0005386	EFO:0004265

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04927247	PHASE3	TERMINATED	A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
NCT04935879	PHASE3	COMPLETED	A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
NCT05348915	PHASE3	TERMINATED	A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
NCT01245634	PHASE2	COMPLETED	A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
NCT01327183	PHASE2	COMPLETED	A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
NCT00760565	PHASE1	COMPLETED	A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).
NCT01815827	PHASE1	COMPLETED	A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
GALLIC ACID	ChEMBL + PubChem	Phase 2 (approved)	SELP
BIMOSIAMOSE	ChEMBL	Phase 2	SELP